Well Referenced

Tag: ivermectin

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug

This 2018 review explores the repositioning of ivermectin, traditionally an antiparasitic agent, as a novel anticancer drug. The article highlights ivermectin’s ability to target multiple molecular pathways critical to cancer cell survival and proliferation. Mechanistically, ivermectin inhibits P-glycoprotein to overcome drug resistance, acts on chloride ion channels to induce apoptosis,

Read More »
June 26, 2025 No Comments

Integrated Analysis Reveals FOXA1 and Ku70/Ku80 as Targets of Ivermectin in Prostate Cancer

This 2022 study investigates ivermectin’s anticancer effects in prostate cancer, identifying FOXA1 and Ku70/Ku80 as direct targets. Ivermectin induces G0/G1 cell cycle arrest, apoptosis, and DNA damage, while suppressing androgen receptor (AR) signaling. It binds to FOXA1, reducing chromatin accessibility of AR signaling and E2F1, leading to inhibited cell proliferation.

Read More »
June 26, 2025 No Comments

Old wine in new bottles: Drug repurposing in oncology

This 2019 review explores drug repurposing as a cost-effective and time-saving strategy in oncology, highlighting its potential to expedite the development of cancer treatments. The authors discuss several non-oncologic drugs—such as artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide—that exhibit anticancer properties through mechanisms like apoptosis induction, angiogenesis inhibition,

Read More »
June 26, 2025 No Comments